Increased risk of cardiovascular disease in women with prior gestational diabetes: A systematic review and meta-analysis

AbstractThe aims of this systematic review and meta-analysis were to describe prevalence of cardiovascular disease in gout, compare these results with non-gout controls and consider whether there were differences according to geography. PubMed, Scopus and Web of Science were systematically searched for studies reporting prevalence of any cardiovascular disease in a gout population. Studies with non-representative sampling, where a cohort had been used in another study, small sample size (< 100) and where gout could not be distinguished from other rheumatic conditions were excluded, as were reviews, editorials and comments. Where possible meta-analysis was performed using random-effect models. Twenty-six studies comprising 949,773 gout patients were included in the review. Pooled prevalence estimates were calculated for five cardiovascular diseases: myocardial infarction (2.8%; 95% confidence interval (CI)s 1.6, 5.0), heart failure (8.7%; 95% CI 2.9, 23.8), venous thromboembolism (2.1%; 95% CI 1.2, 3.4), cerebrovascular accident (4.3%; 95% CI 1.8, 9.7) and hypertension (63.9%; 95% CI 24.5, 90.6). Sixteen studies reported comparisons with non-gout controls, illustrating an increased risk in the gout group across all cardiovascular diseases. There were no identifiable reliable patterns when analysing the results by country. Cardiovascular diseases are more prevalent in patients with gout and should prompt vigilance from clinicians to the need to assess and stratify cardiovascular risk. Future research is needed to investigate the link between gout, hyperuricaemia and increased cardiovascular risk and also to establish a more thorough picture of prevalence for less common cardiovascular diseases.

Download Full-text

Short sleep duration is associated with an increased risk of gestational diabetes: Systematic review and meta-analysis

Proceedings of The Nutrition Society ◽

10.1017/s0029665115004383 ◽

2016 ◽

Vol 75 (OCE1) ◽

Author(s):

A.A. Alghamdi ◽

N.A. Al Afif ◽

G.R. Law ◽

E.M. Scottand ◽

G.TH. Ellison

Keyword(s):

Systematic Review ◽

Gestational Diabetes ◽

Sleep Duration ◽

Meta Analysis ◽

Short Sleep Duration ◽

Short Sleep ◽

Increased Risk

Download Full-text

Is there an increased risk of perinatal mental disorder in women with gestational diabetes? A systematic review and meta‐analysis

Diabetic Medicine ◽

10.1111/dme.14170 ◽

2019 ◽

Vol 37 (4) ◽

pp. 602-622 ◽

Cited By ~ 4

Author(s):

C. A. Wilson ◽

J. Newham ◽

J. Rankin ◽

K. Ismail ◽

E. Simonoff ◽

...

Keyword(s):

Systematic Review ◽

Gestational Diabetes ◽

Mental Disorder ◽

Meta Analysis ◽

Increased Risk

Download Full-text

Relation between Age-Related Macular Degeneration and Cardiovascular Events and Mortality: A Systematic Review and Meta-Analysis

BioMed Research International ◽

10.1155/2016/8212063 ◽

2016 ◽

Vol 2016 ◽

pp. 1-10 ◽

Cited By ~ 11

Author(s):

Jie Wang ◽

Yangjing Xue ◽

Saroj Thapa ◽

Luping Wang ◽

Jifei Tang ◽

...

Keyword(s):

Systematic Review ◽

Cardiovascular Disease ◽

Macular Degeneration ◽

Cardiovascular Events ◽

Meta Analysis ◽

Age Related Macular Degeneration ◽

Relative Risks ◽

Age Related ◽

Increased Risk ◽

All Cause Mortality

Data on the association between age-related macular degeneration (AMD) and cardiovascular disease and mortality are conflicting. The purpose of this report is to conduct a systematic review to better understand the role of AMD as a risk factor for CVD events and mortality. We searched Medline (Ovid) and Embase (Ovid) for trials published from 1980 to 2015. We included 20 cohort studies that reported relative risks with 95% confidence intervals for the association of AMD and cardiovascular events and mortality, involving 29,964,334 participants. In a random-effects model, the adjusted RR (95% confidence interval [CI]) associated with AMD was 1.08 (1.00–1.117) for all-cause mortality (8 studies) and 1.18 (0.98–1.43) for cardiovascular disease mortality (5 studies). The pooled RR (95% CI) was 1.17 (0.94–1.45) for coronary heart disease (CHD; 3 studies) and 1.13 (0.93–1.36) for stroke (8 studies). Findings from this systematic review support that AMD is associated with increased risk of all-cause mortality. The evidence that AMD predicts incident CVD events or CVD mortality remains inclusive and warrants further study in the future.

Download Full-text

Gallstone Disease and the Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Observational Studies

Scandinavian Journal of Surgery ◽

10.1177/1457496916650998 ◽

2016 ◽

Vol 106 (1) ◽

pp. 21-27 ◽

Cited By ~ 10

Author(s):

S. Upala ◽

A. Sanguankeo ◽

V. Jaruvongvanich

Keyword(s):

Risk Factors ◽

Systematic Review ◽

Cardiovascular Disease ◽

Confidence Interval ◽

Cardiovascular Events ◽

Meta Analysis ◽

Gallstone Disease ◽

Hazard Ratio ◽

Cross Sectional ◽

Increased Risk

Objectives: Gallstone disease shares certain risk factors with cardiovascular disease, particularly metabolic risk factors. Patients with gallstone disease may be at increased risk of cardiovascular disease. Several recent studies exploring the effect of gallstone disease on cardiovascular disease outcomes demonstrated inconsistent results. Design: We conducted a systematic review and meta-analysis of cohort, case–control, and cross-sectional studies that compared the risk of developing cardiovascular disease events in patients with gallstone disease versus non-gallstone disease controls. Data from each study were combined using the random-effects, generic inverse variance method of DerSimonian and Laird to calculate the pooled hazard ratio, odd ratio, and 95% confidence interval. Results: Data were extracted from six studies involving 176,734 cases and 803,714 controls. The pooled hazard ratio of cardiovascular events in patients with gallstone disease was 1.28 (95% confidence interval: 1.23–1.33, I2 = 42%). The pooled odd ratio of cardiovascular events in patients with gallstone disease was 1.82 (95% confidence interval: 1.47–2.24, I2 = 68%). Conclusions: Our study demonstrated a statistically significant increase in the risk of cardiovascular disease among patients with gallstone disease.

Download Full-text

Pre-Eclamptic Pregnancies: An Opportunity to Identify Women at Risk for Future Cardiovascular Disease

Women s Health ◽

10.2217/17455057.4.2.133 ◽

2008 ◽

Vol 4 (2) ◽

pp. 133-135 ◽

Cited By ~ 25

Author(s):

Iasmina M Craici ◽

Steven J Wagner ◽

Suzanne R Hayman ◽

Vesna D Garovic

Keyword(s):

Systematic Review ◽

Cardiovascular Disease ◽

Risk Factor ◽

Meta Analysis ◽

Later Life ◽

Future Studies ◽

Increased Risk ◽

All Cause Mortality ◽

History Of

Evaluation of: Bellamy L, Casas JP, Hingorani AD, Williams DJ: Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br. Med. J. 335(7627), 974 (2007). Evidence has emerged over the years suggesting that women who develop hypertensive pregnancy disorders, most notably pre-eclampsia, are at an increased risk for cardiovascular disease later in life. In this study, a systematic review and meta-analysis were performed, assessing the future risks of cardiovascular disease, cancer and all-cause mortality in women with a history of pre-eclampsia and eclampsia. Women with a history of pre-eclampsia or eclampsia, compared with women without such a history, had an increased risk for cardiovascular disease, including a fourfold increased risk for hypertension, a twofold increased risk for ischemic heart disease, stroke and deep venous thrombosis, and a 1.5-times higher all-cause mortality. The study suggests that affected women may be eligible for preventive therapies at an earlier age, especially if future studies establish the role of pre-eclampsia as an independent cardiovascular risk factor.

Download Full-text

Body-Weight Fluctuation Was Associated With Increased Risk for Cardiovascular Disease, All-Cause and Cardiovascular Mortality: A Systematic Review and Meta-Analysis

Frontiers in Endocrinology ◽

10.3389/fendo.2019.00728 ◽

2019 ◽

Vol 10 ◽

Cited By ~ 5

Author(s):

Huajie Zou ◽

Ping Yin ◽

Liegang Liu ◽

Wenhua Liu ◽

Zeqing Zhang ◽

...

Keyword(s):

Systematic Review ◽

Cardiovascular Disease ◽

Body Weight ◽

Cardiovascular Mortality ◽

Meta Analysis ◽

Weight Fluctuation ◽

Increased Risk

Download Full-text

Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis

Intervirology ◽

10.1159/000512592 ◽

2020 ◽

pp. 1-12

Author(s):

Mohitosh Biswas ◽

Shawonur Rahaman ◽

Tapash Kumar Biswas ◽

Zahirul Haque ◽

Baharudin Ibrahim

Keyword(s):

Systematic Review ◽

Cardiovascular Disease ◽

Meta Analysis ◽

Statistical Significance ◽

Considerable Proportion ◽

Relative Risks ◽

Risk Of Mortality ◽

Increased Risk ◽

Male Patients ◽

Reduce Risk

Introduction: Although severe acute respiratory syndrome coronavirus-2 infection is causing mortality in considerable proportion of coronavirus disease-2019 (COVID-19) patients, however, evidence for the association of sex, age, and comorbidities on the risk of mortality is not well-aggregated yet. It was aimed to assess the association of sex, age, and comorbidities with mortality in COVID-2019 patients. Methods: Literatures were searched using different keywords in various databases. Relative risks (RRs) were calculated by RevMan software where statistical significance was set as p < 0.05. Results: COVID-19 male patients were associated with significantly increased risk of mortality compared to females (RR 1.86: 95% confidence interval [CI] 1.67–2.07; p < 0.00001). Patients with age ≥50 years were associated with 15.4-folds significantly increased risk of mortality compared to patients with age <50 years (RR 15.44: 95% CI 13.02–18.31; p < 0.00001). Comorbidities were also associated with significantly increased risk of mortality; kidney disease (RR 4.90: 95% CI 3.04–7.88; p < 0.00001), cereborovascular disease (RR 4.78; 95% CI 3.39–6.76; p < 0.00001), cardiovascular disease (RR 3.05: 95% CI 2.20–4.25; p < 0.00001), respiratory disease (RR 2.74: 95% CI 2.04–3.67; p < 0.00001), diabetes (RR 1.97: 95% CI 1.48–2.64; p < 0.00001), hypertension (RR 1.95: 95% CI 1.58–2.40; p < 0.00001), and cancer (RR 1.89; 95% CI 1.25–2.84; p = 0.002) but not liver disease (RR 1.64: 95% CI 0.82–3.28; p= 0.16). Conclusion: Implementation of adequate protection and interventions for COVID-19 patients in general and in particular male patients with age ≥50 years having comorbidities may significantly reduce risk of mortality associated with COVID-19.

Download Full-text